Subsequently, we examined the viability and proliferative abilities of the four GC cell lines (SGC7901, SGC803, BGC823 and AGS) in response to different PI3K inhibitors, including acalisib, compound 7n and idelalisib, at a series of concentrations. This evidence concerns the gene PIK3CB and gastric cancer.